Literature DB >> 21777270

QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus.

Emanuel Raschi, Elisabetta Poluzzi, Ariola Koci, Giuseppe Boriani, Fabrizio De Ponti.   

Abstract

Mesh：

Year:  2011        PMID： 21777270      PMCID： PMC3243020          DOI： 10.1111/j.1365-2125.2011.04065.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

Review 1.  Drug-induced long QT syndrome.

Authors:  Prince Kannankeril; Dan M Roden; Dawood Darbar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives.

Authors:  Rashmi R Shah
Journal:  Br J Pharmacol       Date:  2009-06-25       Impact factor: 8.739

Review 3.  Short QT syndrome: mechanisms, diagnosis and treatment.

Authors:  Preben Bjerregaard; Ihor Gussak
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2005-02

Review 4.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

5.  Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?

Authors:  Mark Holbrook; Marek Malik; Rashmi R Shah; Jean-Pierre Valentin
Journal:  J Pharmacol Toxicol Methods       Date:  2008-09-17       Impact factor: 1.950
  5 in total
  4 in total

1.  Drug-induced QT-interval shortening following antiepileptic treatment with oral rufinamide.

Authors:  Rainer Schimpf; Christian Veltmann; Theano Papavassiliu; Boris Rudic; Turgay Göksu; Jürgen Kuschyk; Christian Wolpert; Charles Antzelevitch; Alois Ebner; Martin Borggrefe; Christian Brandt
Journal:  Heart Rhythm       Date:  2012-01-11       Impact factor: 6.343

2.  Evidence for cardiotoxicity associated with sertraline in rats.

Authors:  Sinem Ilgin; Volkan Kilic; Merve Baysal; Gozde Aydogan-Kilic; Seyda Ucarcan; Begum Dermenci; Ozlem Atli
Journal:  Toxicol Res (Camb)       Date:  2018-04-06       Impact factor: 3.524

3.  Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.

Authors:  Elisabetta Poluzzi; Emanuel Raschi; Ariola Koci; Ugo Moretti; Edoardo Spina; Elijah R Behr; Miriam Sturkenboom; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

4.  The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.

Authors:  Charles E Leonard; Colleen M Brensinger; Ghadeer K Dawwas; Rajat Deo; Warren B Bilker; Samantha E Soprano; Neil Dhopeshwarkar; James H Flory; Zachary T Bloomgarden; Joshua J Gagne; Christina L Aquilante; Stephen E Kimmel; Sean Hennessy
Journal:  Cardiovasc Diabetol       Date:  2020-02-25       Impact factor: 9.951
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.